Dexmedetomidine and Propofol for Pediatric MRI Sedation
Headache, Tumor, Seizure Disorder
About this trial
This is an interventional treatment trial for Headache
Eligibility Criteria
Inclusion Criteria:
- All children scheduled for outpatient MRI scans with expected duration of scan between 30 minutes and 75 minutes.
Exclusion Criteria:
- Inpatient status, airway abnormalities, allergy to any study medications, eggs and soy, and mitochondrial disorders.
- All subjects with any cardiac disease or history of cardiac arrhythmias will be excluded.
Sites / Locations
- Children's Hospital of Wisconsin
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
propofol
propofol dexmedetomidine
Each patient will receive 1 mg/kg lidocaine followed by 2 mg/kg propofol IV once prior to continuous propofol infusion for MRI sedation at 200 mcg/kg/min. Dose will be increased by 50 mcg/kg/min up to 300 mcg/kg/min for movement and decreased to 150 mcg/kg/min if no movement after 30 minutes. Additional 1 mg/kg propofol bolus administered at time of each movement. Study to be terminated if movement persists despite above interventions.
Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mcg/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mcg/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mcg/kg/min. Study to be terminated if movement persists despite above interventions.